Torna al Registre Simple

 

Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPalma-Alvarez, Raul Felipe
dc.contributor.authorBarta, Csaba
dc.contributor.authorCarpentier, Pieter Jan
dc.contributor.authorCarruthers, Susan
dc.contributor.authorCrunelle, Cleo
dc.contributor.authorDemetrovics, Zsolt
dc.contributor.authorRamos-Quiroga, Josep Antoni
dc.date.accessioned2023-11-17T08:36:47Z
dc.date.available2023-11-17T08:36:47Z
dc.date.issued2023-01
dc.identifier.citationPalma-Álvarez RF, Barta C, Carpentier PJ, Carruthers S, Crunelle CL, Demetrovics Z, et al. Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. Span J Psychiatry Ment Heal. 2023 Jan-Mar;16(1):11–5.
dc.identifier.issn2950-2853
dc.identifier.urihttps://hdl.handle.net/11351/10621
dc.descriptionComorbilitat; Psicometria; Trastorn per consum de substàncies
dc.description.sponsorshipThe IASP study was funded by several institutions in each country. The ICASA Foundation developed the study and coordinated with each institution the regional funding process. The funding sources did not have any influence on the study (research protocol, sampling, issues, analyses, publication). Australia: a strategic grant from Curtin University of Technology (Perth, Western Australia) funded the IAS screening phase. Belgium: the IASP project in this country received private funding. Hungary: No direct funding was received, it was supported by a grant from The European Union and European Social Fund (under agreement to finance the project) no. TÁMOP 4.2.1./B-09/1/KMR-2010-0003. The Netherlands, Amsterdam: no external funding was obtained. The participating institute, Arkin, paid for the costs involved. Norway, Bergen Clinics Foundation: 50% of funding was provided by the Regional Research Council For Addiction in West Norway (Regionalt kompetansesenter for rusmiddelforskning I Helse Vest (KORFOR); the remaining 50% was supported by Bergen Clinics Foundation (Staff and infrastructure). Norway, Fredrikstad: The IASP was funded by the hospital (Sykehuset Østfold HF) not with money, but with 50% of the salary of the participants, then by two sources outside the hospital: The Regional center of Dual Diagnosis and the social – and Health directory. Spain, Barcelona: Financial support was received from Plan Nacional sobre Drogas, Ministerio de Sanidad y Política Social (PND 0080/2011), the Agència de Salut Pública de Barcelona and the Departament de Salut, Government of Catalonia, Spain. Sweden, Stockholm: The study was funded by the Stockholm Center for Dependency Disorders. Switzerland, Berne/Zurich: The IASP in Switzerland was funded by the Swiss Foundation of Alcohol Research (Grant # 209). USA, Syracuse: no funding was obtained. The funding sources did not have influence on: who participated as an author in this study; the research protocol; the sampling of data; the topics chosen for publications; the analyses of the data; the content of the publication.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesSpanish Journal of Psychiatry and Mental Health;16(1)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectTrastorn per dèficit d'atenció amb hiperactivitat - Diagnòstic
dc.subjectAbús de substàncies
dc.subjectMalalties mentals
dc.subjectTests neuropsicològics
dc.subject.meshAttention Deficit Disorder with Hyperactivity
dc.subject.mesh/diagnosis
dc.subject.meshSubstance-Related Disorders
dc.subject.meshPsychiatric Status Rating Scales
dc.titleValidity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.rpsm.2020.04.013
dc.subject.decstrastornos de déficit de atención con hiperactividad
dc.subject.decs/diagnóstico
dc.subject.decstrastornos relacionados con sustancias
dc.subject.decsescalas de valoración psiquiátrica
dc.relation.publishversionhttps://doi.org/10.1016/j.rpsm.2020.04.013
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Palma-Álvarez RF, Ramos-Quiroga JA] Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Barta C] Institute of Medical Chemistry, Molecular Biology, Pathobiochemistry, Semmelweis University, Budapest, Hungary. [Carpentier PJ] Reinier van Arkel mental health institute, ‘s-Hertogenbosch, The Netherlands. [Carruthers S] National Drug Research Institute, Curtin University, Perth, Australia. [Crunelle CL] Department of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Toxicological Center, Antwerp University, Antwerp, Belgium. [Demetrovics Z] Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
dc.identifier.pmid32561156
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Name:
validity_adhd_module_mini_inte ...
Grandària:
381.6Kb
Format:
PDF
Description:
Validity of the ADHD module of ...
Visualitza

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple